LLY
NVO
The floodgates are opening
Medicare’s new weight-loss drug program kicks off on July 1, and doctors are basically saying: get ready for the waiting room to become a zoo. Eligible seniors will be able to access obesity drugs like Wegovy and Zepbound for a $50 monthly copay, which is a lot less painful than sticker shock at the pharmacy counter.
Why this matters for investors
This is a big deal because Medicare has historically not covered weight-loss meds, so the rollout could create a sudden wave of new demand. With roughly 14 million Medicare beneficiaries overweight or obese, the number of people trying to get on GLP-1s could jump fast — and fast demand is catnip for drugmakers.
The catch: healthcare friction, meet reality
The fine print is where things get messy:
- Patients still need prior authorization, which means extra paperwork before the first prescription
- Clinics may have to monitor side effects, dosing, and frailty risk in older adults
- Medicare doesn’t cover the nutrition and behavioral support that often makes obesity treatment actually work
- The program is temporary, running through the end of 2027, which adds a little “use it before you lose it” energy
That combo could overwhelm already busy practices. In other words: more demand for the drugs, yes — but also more strain on the system that hands them out.
The GLP-1 gold rush, but with speed bumps
Novo Nordisk and Eli Lilly are the obvious winners if access expands the way advocates expect. But insurers are also tightening the screws elsewhere, and rising drug costs are already pushing employers to clamp down on coverage. So this is less of a clean victory lap and more of a messy buffet line.
Big picture: Medicare just threw open a bigger door for GLP-1s — and the companies making them may love the volume, even if doctors don’t love the traffic jam.